Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin

被引：50

作者：

Ikezoe, T. ^{[1
]}

Togitani, K. ^{[1
]}

Komatsu, N. ^{[1
]}

Isaka, M. ^{[1
]}

Yokoyama, A. ^{[1
]}

机构：

[1] Kochi Univ, Dept Hematol & Resp Med, Nanko Ku, Kochi 780, Japan

来源：

BONE MARROW TRANSPLANTATION | 2010年 / 45卷 / 04期

关键词：

HEPATIC VENOOCCLUSIVE DISEASE; DEFIBROTIDE; PROTEIN;

D O I：

10.1038/bmt.2009.217

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

引用

页码：783 / 785

页数：3

共 10 条

[1] The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism [J].

Abeyama, K ;

Stern, DM ;

Ito, Y ;

Kawahara, K ;

Yoshimoto, Y ;

Tanaka, M ;

Uchimura, T ;

Ida, N ;

Yamazaki, Y ;

Yamada, S ;

Yamamoto, Y ;

Yamamoto, H ;

Iino, S ;

Taniguchi, N ;

Maruyama, I .

JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (05) :1267-1274

[2] Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome [J].

DeLeve, LD ;

Ito, Y ;

Bethea, NW ;

McCuskey, MK ;

Wang, XD ;

McCuskey, RS .

AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2003, 284 (06) :G1045-G1052

[3]

Haussmann U, 2006, HAEMATOLOGICA, V91, P795

[4] Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies [J].

Ho, V. T. ;

Revta, C. ;

Richardson, P. G. .

BONE MARROW TRANSPLANTATION, 2008, 41 (03) :229-237

[5] Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation [J].

Kumar, S ;

DeLeve, LD ;

Kamath, PS ;

Tefferi, A .

MAYO CLINIC PROCEEDINGS, 2003, 78 (05) :589-598

[6]

Maruyama I, 1999, THROMB HAEMOSTASIS, V82, P718

[7] VENO-OCCLUSIVE DISEASE OF THE LIVER AFTER BONE-MARROW TRANSPLANTATION - DIAGNOSIS, INCIDENCE, AND PREDISPOSING FACTORS [J].

MCDONALD, GB ;

SHARMA, P ;

MATTHEWS, DE ;

SHULMAN, HM ;

THOMAS, ED .

HEPATOLOGY, 1984, 4 (01) :116-122

[8] Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome [J].

Richardson, PG ;

Murakami, C ;

Jin, ZZ ;

Warren, D ;

Momtaz, P ;

Hoppensteadt, D ;

Elias, AD ;

Antin, JH ;

Soiffer, R ;

Spitzer, T ;

Avigan, D ;

Bearman, SI ;

Martin, PL ;

Kurtzberg, J ;

Vredenburgh, J ;

Chen, AR ;

Arai, S ;

Vogelsang, G ;

McDonald, GB ;

Guinan, EC .

BLOOD, 2002, 100 (13) :4337-4343

[9] Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation [J].

Ruutu, T ;

Eriksson, B ;

Remes, K ;

Juvonen, E ;

Volin, L ;

Remberger, M ;

Parkkali, T ;

Hägglund, H ;

Ringdén, O .

BLOOD, 2002, 100 (06) :1977-1983

[10] Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial [J].

Saito, H. ;

Maruyama, I. ;

Shimazaki, S. ;

Yamamoto, Y. ;

Aikawa, N. ;

Ohno, R. ;

Hirayama, A. ;

Matsuda, T. ;

Asakura, H. ;

Nakashima, M. ;

Aoki, N. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (01) :31-41

← 1 →